| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Other Events |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2023 |
8-K
| Other Events |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/21/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/09/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/05/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/04/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/19/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/11/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/11/2022 |
8-K/A
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Unaudited Pro Forma Condensed Consolidated Financial Information Overview On June 30, 2022 , Acutus Medical, Inc. completed its previously announced transaction with Medtronic, Inc. , in accordance with the Asset Purchase Agreement executed on April 26, 2022, and pursuant to which the Company sold to Medtronic certain transseptal access and sheath assets . The Assets include patents, trademarks, patent and trademark applications, know-how, copyrights, prototypes and other intellectual property owned or licensed by the Company, business records and documents , and manufacturing equipment related to the AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and ..." |
|
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/29/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/21/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 07/15/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/05/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|